Ji-Feng Feng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6213834/publications.pdf

Version: 2024-02-01

331670 223800 5,027 50 21 46 h-index citations g-index papers 52 52 52 6657 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PELI1 promotes radiotherapy sensitivity by inhibiting noncanonical NFâ€PB in esophageal squamous cancer. Molecular Oncology, 2022, 16, 1384-1401.	4.6	8
2	Water-soluble BODIPY-nido-carborane nanoparticles applied to biocompatibility tumor cell imaging. Photochemical and Photobiological Sciences, 2022, 21, 185-194.	2.9	3
3	A Three-Genes Signature Predicting Colorectal Cancer Relapse Reveals LEMD1 Promoting CRC Cells Migration by RhoA/ROCK1 Signaling Pathway. Frontiers in Oncology, 2022, 12, .	2.8	3
4	SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and $TGF\hat{l}^2$, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study. Clinical Cancer Research, 2022, 28, 5297-5305.	7.0	20
5	Therapeutic Strategies for Resectable Stage-IIIA N2 Non–Small Cell Lung Cancer Patients: A Network Meta-Analysis. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211094.	1.3	O
6	Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 589-607.	2.0	29
7	CDCA4 suppresses epithelial–mesenchymal transtion (EMT) and metastasis in Non-small cell lung cancer through modulating autophagy. Cancer Cell International, 2021, 21, 48.	4.1	13
8	Role of ATP5B in colorectal cancer. Precision Medical Sciences, 2021, 10, 21-25.	0.5	O
9	Hypermethylation of heparanase 2 promotes colorectal cancer proliferation and is associated with poor prognosis. Journal of Translational Medicine, 2021, 19, 98.	4.4	12
10	Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors. BioMed Research International, 2021, 2021, 1-8.	1.9	O
11	VLX1570 regulates the proliferation and apoptosis of human lung cancer cells through modulating ER stress and the AKT pathway. Journal of Cellular and Molecular Medicine, 2021, , .	3.6	6
12	LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. Cell Death and Disease, 2020, 11, 525.	6.3	38
13	In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer. Journal of Cancer, 2020, 11, 7216-7223.	2.5	1
14	Hsa_circ_0046263 functions as a ceRNA to promote nasopharyngeal carcinoma progression by upregulating IGFBP3. Cell Death and Disease, 2020, 11, 562.	6.3	30
15	B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma. Pathology Research and Practice, 2020, 216, 153134.	2.3	15
16	New genetic variations discovered in KRAS wildâ€type cetuximab resistant chinese colorectal cancer patients. Molecular Carcinogenesis, 2020, 59, 478-491.	2.7	10
17	Serum Platelet-Derived Growth Factor Is Significantly Lower in Patients with Lung Cancer and Continued to Decrease After Platinum-Based Chemotherapy. OncoTargets and Therapy, 2020, Volume 13, 1883-1892.	2.0	5
18	CRNDE: an oncogenic long non-coding RNA in cancers. Cancer Cell International, 2020, 20, 162.	4.1	46

#	Article	IF	Citations
19	DNA‑methylated gene markers for colorectal cancer in TCGA database. Experimental and Therapeutic Medicine, 2020, 19, 3042-3050.	1.8	10
20	p38/TF/HIF-l \pm Signaling Pathway Participates in the Progression of CIPN in Mice. BioMed Research International, 2019, 2019, 1-11.	1.9	5
21	Integrated Analysis of Oncogenic Networks in Colorectal Cancer Identifies GUCA2A as a Molecular Marker. Biochemistry Research International, 2019, 2019, 1-13.	3.3	24
22	Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer. Journal of Cellular Biochemistry, 2019, 120, 10767-10776.	2.6	19
23	Long noncoding RNAs predict the survival of patients with colorectal cancer as revealed by constructing an endogenous RNA network using bioinformation analysis. Cancer Medicine, 2019, 8, 863-873.	2.8	29
24	<p>The Role Of Circulating Tumor DNA In Therapeutic Resistance</p> . OncoTargets and Therapy, 2019, Volume 12, 9459-9471.	2.0	9
25	Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. Biomedicine and Pharmacotherapy, 2019, 109, 2327-2334.	5.6	33
26	Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinibâ€resistant lung adenocarcinoma cells. Cancer Medicine, 2018, 7, 1955-1966.	2.8	11
27	Tâ€eell lymphomas associated gene expression signature: Bioinformatics analysis based on gene expression Omnibus. European Journal of Haematology, 2018, 100, 575-583.	2.2	2
28	6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound. Bioscience Reports, 2018, 38, .	2.4	17
29	MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment. Journal of Cancer Research and Clinical Oncology, 2018, 144, 431-438.	2.5	23
30	Glutathione S -transferase π: a potential role in antitumor therapy. Drug Design, Development and Therapy, 2018, Volume 12, 3535-3547.	4.3	51
31	Advances of circular RNAs in carcinoma. Biomedicine and Pharmacotherapy, 2018, 107, 59-71.	5.6	21
32	LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Clinical and Experimental Medicine, 2017, 17, 1-8.	3.6	41
33	Chimaeric antigen receptor T-cell therapy for tumour immunotherapy. Bioscience Reports, 2017, 37, .	2.4	13
34	Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to <scp>EGFR</scp> â€ <scp>TKI</scp> treatment. FEBS Open Bio, 2017, 7, 35-43.	2.3	8
35	PPARÎ ³ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARÎ ³ /PTEN/Akt pathway. Experimental Cell Research, 2017, 361, 246-256.	2.6	28
36	High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma. Experimental Cell Research, 2017, 361, 126-134.	2.6	28

#	Article	IF	CITATIONS
37	Age is associated with prognosis in serous ovarian carcinoma. Journal of Ovarian Research, 2017, 10, 36.	3.0	28
38	Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner. International Journal of Nanomedicine, 2017, Volume 12, 3721-3733.	6.7	195
39	Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB <i>in vitro</i> . Oncotarget, 2017, 8, 15802-15814.	1.8	12
40	Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. Oncotarget, 2017, 8, 18901-18913.	1.8	24
41	Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomedicine and Pharmacotherapy, 2016, 79, 188-193.	5.6	62
42	Notch-1 Confers Chemoresistance in Lung Adenocarcinoma to Taxanes through AP-1/microRNA-451 Mediated Regulation of MDR-1. Molecular Therapy - Nucleic Acids, 2016, 5, e375.	5.1	35
43	Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomedicine and Pharmacotherapy, 2016, 77, 65-71.	5.6	48
44	Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. Clinical and Experimental Medicine, 2016, 16, 177-182.	3.6	54
45	Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis. Scientific Reports, 2015, 5, 10516.	3.3	11
46	Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumor Biology, 2015, 36, 6751-6758.	1.8	70
47	Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology. Oncology Letters, 2014, 7, 499-506.	1.8	12
48	Expression of growth-regulated oncogene-1, hepatocyte growth factor, platelet-derived growth factor-AA and soluble E-selectin and their association with high-risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix. Molecular Medicine Reports, 2014, 10, 1013-1024.	2.4	15
49	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2011, 12, 735-742.	10.7	3,758
50	MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 437-446.	2.3	92